Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | POLB | P06746 | 3/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5409719 | 0.83 | SMN1; SMN2 (0.41) | MAPTALDH1A1POLBHTTMEN1 | |
| SCHEMBL8920097 | 0.74 | CYP3A4 (0.44) | MAPTLMNAALDH1A1POLBHTT | |
| SCHEMBL5399448 | 0.72 | CYP3A4 (0.43) | MAPTLMNAALDH1A1POLBHTT | |
| SCHEMBL5411987 | 0.72 | ALDH1A1 (0.35) | MAPTLMNAALDH1A1POLBHTT | |
| SCHEMBL5382948 | 0.72 | LMNA (0.49) | MAPTLMNAALDH1A1POLBHTT | |
| SCHEMBL2930475 | 0.71 | SMN1; SMN2 (0.39) | MAPTLMNAALDH1A1POLBHTT | |
| SCHEMBL5409732 | 0.71 | GRIA1 (0.35) | MAPTLMNAALDH1A1POLBHTT | |
| SCHEMBL27603443 | 0.70 | SMN1; SMN2 (0.40) | MAPTSMN1; SMN2 | |
| SCHEMBL14401656 | 0.70 | POLB (0.36) | LMNAPOLBHTTMEN1KMT2A | |
| SCHEMBL8920031 | 0.69 | ALDH1A1 (0.36) | MAPTLMNAALDH1A1POLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7300469-B2 | Diaminopyrazole compounds and the use thereof in the oxidation dyeing of keratinous fibres | L'OREAL, SA (FR) | 2007-11-27 | — | — | US | disclosed |
| US-20040143909-A1 | Diaminopyrazole compounds and the use thereof in the oxidation dyeing of keratinous fibres | L'OREAL S.A. (FR) | 2004-07-29 | — | — | US | disclosed |
| EP-1362036-A1 | DIAMINOPYRAZOLE COMPOUNDS AND THE USE THEREOF IN THE OXIDATION DYEING OF KERATINOUS FIBRES | L'OREAL (FR) | 2003-11-19 | — | — | EP | disclosed |
| US-20030125367-A1 | Bicyclo[3,1,0]hexane containing oxazolidinone antibioytics and derivatives thereof | KYORIN PHARMACEUTICAL CO., LTD. | 2003-07-03 | — | — | US | disclosed |
| WO-2002070489-A1 | DIAMINOPYRAZOLE COMPOUNDS AND THE USE THEREOF IN THE OXIDATION DYEING OF KERATINOUS FIBRES | L'OREAL (FR) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125367-A1 | Bicyclo[3,1,0]hexane containing oxazolidinone antibioytics and derivatives thereof | NR4A1, NR0B1, NR1D1 | MAPT 4217/4885LMNA 3824/4885ALDH1A1 708/4885 |
| US-20040143909-A1 | Diaminopyrazole compounds and the use thereof in the oxidation dyeing of keratinous fibres | KRT18, TUBB3, AOC1 | MAPT 1794/4885LMNA 910/4885ALDH1A1 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.